FDA Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
RBC Capital Affirms Amgen (AMGN) at 'Outperform'; Repatha Approval Similar to Praluent (REGN) (SNY)
August 28, 2015 7:22 AM EDTRBC Capital is out with commentary on Amgen (Nasdaq: MGN) following news that the U.S. FDA apprvoed the company's new cholesterol-lowering medication, Repatha (evolocumab) Injection.
Analyst Michael J. Yee noted that Repatha's approval is similar to Regeneron and Sanofi's Praluent. Yee continued:
Repatha approval is for "use in addition to diet and maximally-tolerated statin therapy in adult patients with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), or... More
Amgen (AMGN) Announces FDA Approval of Repatha for Lowering LDL-C
August 28, 2015 6:23 AM EDTAmgen (NASDAQ: AMGN) announced that the U.S. Food and Drug Administration (FDA) has approved a new cholesterol-lowering medication, Repatha (evolocumab) Injection. Repatha is a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces the liver's ability to remove low-density lipoprotein cholesterol (LDL-C), or "bad" cholesterol, from the blood.1 Repatha is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD), who require additional lowering of LDL-C; and as an adjunct to... More
